Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.52 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574904 | 0.87 | TAAR1 (0.40) | PNMTTAAR1HTR2A | |
| SCHEMBL8126752 | 0.86 | PNMT (0.48) | PNMTDPP4TAAR1HTR2ALOXL2 | |
| SCHEMBL15247 | 0.81 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| SCHEMBL29405036 | 0.81 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| SCHEMBL9057723 | 0.79 | PNMT (0.45) | PNMTDPP4TAAR1LOXL2 | |
| SCHEMBL3051426 | 0.79 | TAAR1 (0.61) | PNMTDPP4TAAR1HTR2ALOXL2 | |
| SCHEMBL10534341 | 0.79 | TSHR (0.41) | PNMTTAAR1HTR2A | |
| SCHEMBL7865281 | 0.79 | PNMT (0.56) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| SCHEMBL28683639 | 0.78 | PNMT (0.62) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| Hydrochloric Acid SCHEMBL2522138 | 0.78 | PNMT (0.60) | PNMTDPP4TAAR1LOXL2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| CN-1227489-A | Adenosine deaminase inhibitors | GOVERNORS FOR HIGH EDUCATION S (US) | 1999-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | PNMT 1835/4885DPP4 3682/4885TAAR1 2838/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | PNMT 1835/4885DPP4 3682/4885TAAR1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.